12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Other News

Sun Pharmaceutical, Teva, Apotex, AstraZeneca, Aurobindo, Cobalt Laboratories Inc., Glenmark, Mylan, Novartis, Par Pharmaceutical, Torrent, Watson, Brigham and

The U.S. Court of Appeals for the Federal Circuit upheld a lower court decision finding that the U.S. substance patent covering AstraZeneca's cardiovascular drug Crestor rosuvastatin is valid and enforceable. In 2010, the U.S. District Court for the District of Delaware ruled in a consolidated case that ANDA submissions from eight generic manufacturers, including...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >